<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02971826</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL16_0571</org_study_id>
    <nct_id>NCT02971826</nct_id>
  </id_info>
  <brief_title>Use of the Thrombectomy Device ReVive™ SE in the Acute Treatment of Stroke</brief_title>
  <acronym>REVIVE SE</acronym>
  <official_title>Use of the Thrombectomy Device ReVive™ SE in the Acute Treatment of Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The last marketed thrombectomy devices, named stentretriever, permit a better and faster
      recanalization in patient with a stroke. The REVIVETM SE is a device designed to restore the
      brain perfusion in patient with an intracranial artery occlusion. The REVIVETM Se device is
      not widely use in Europe and in France. The objective of this study is to assess the interest
      of using this device in the standard care of ischemic stroke in the radiology unit of the
      hospital Pierre Wertheimer, Lyon. The medical care will not be modified but data will be
      collected in order to determine whether or not this device is useful for the practice of the
      radiology unit.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2018</start_date>
  <completion_date type="Anticipated">December 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of patients with a TICI score of 2b or 3 just after the thrombectomy</measure>
    <time_frame>up to 2 days</time_frame>
    <description>The TICI score is a grading system which evaluate the degree of reperfusion as seen on arteriography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of the other devices use during the thrombectomy (Gidewire, catheter, etc.)</measure>
    <time_frame>up to 2 days</time_frame>
    <description>Review of the medical report which collected the devices used</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of other procedures to treat the patient (thrombolysis, thromboaspiration, etc)</measure>
    <time_frame>Day 0</time_frame>
    <description>Review of the medical report which collected the acute treatments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to obtain the appropriate recanalization (TICI 2b or 3)</measure>
    <time_frame>At the end of the procedure - Day 0</time_frame>
    <description>Time of recanalization reported by the investigator on the medical report</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>Thrombectomy using the REVIVETM SE device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Thrombectomy using the REVIVETM SE device in patient with an ischemic stroke</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>REVIVETM SE thrombectomy</intervention_name>
    <description>Mechanical thrombectomy using the REVIVETM SE device in patient with an ischemic stroke due to an intracranial arterial occlusion</description>
    <arm_group_label>Thrombectomy using the REVIVETM SE device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with an ischemic stroke detected by Computed Tomography (CT) or Magnetic
             Resonance Image (MRI)

          -  Large proximal arterial occlusion : M1 segment of the Middle cerebral artery (MCA),
             Internal Carotid Artery (ICA) or Basilar Artery (BA)

          -  Last known well (without neurological symptoms) ≤ 8 hours of treatment initiation

          -  Score NIHSS ≥4

          -  Eligibility on an endovascular procedure using REVIVETM SE device

          -  No opposition of the patient to participate at the study

        Exclusion Criteria:

          -  Diagnostic cerebral imaging impossible

          -  Distal occlusion

          -  Tortuous vessel or other specificity preventing the access of device

          -  Vessel diameter &lt; 1.5 mm

          -  Known hypersensibility or allergy to nitinol

          -  Subjects not covered by or having the right to social security

          -  Deprivation of civil rights (guardianship, safeguard justice)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Françis TURJMAN</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospices Civils de Lyon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Françis TURJMAN, MD</last_name>
    <phone>4 7235 74 05</phone>
    <phone_ext>+33</phone_ext>
    <email>francis.turjman@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Claire Jossan</last_name>
    <phone>4 27 86 66 90</phone>
    <phone_ext>+33</phone_ext>
    <email>claire.jossan@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospices Civils de Lyon - Neuroradiology unit</name>
      <address>
        <city>Bron</city>
        <zip>69500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Françis TURJMAN, MD</last_name>
      <phone>4 7235 74 05</phone>
      <phone_ext>+33</phone_ext>
      <email>francis.turjman@chu-lyon.fr</email>
    </contact>
    <contact_backup>
      <last_name>Claire Jossan</last_name>
      <phone>4 27 86 66 90</phone>
      <phone_ext>+33</phone_ext>
      <email>claire.jossan@chu-lyon.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Françis TURJMAN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paul-Emile LABEYRIE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Roberto RIVA, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Benjamin GORY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 16, 2016</study_first_submitted>
  <study_first_submitted_qc>November 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 23, 2016</study_first_posted>
  <last_update_submitted>February 22, 2018</last_update_submitted>
  <last_update_submitted_qc>February 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stroke</keyword>
  <keyword>thrombectomy</keyword>
  <keyword>REVIVETM SE</keyword>
  <keyword>MRI</keyword>
  <keyword>Computed Tomography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

